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osting by EAbstract Hepatotoxicity is a major side-effect of the medicines used in tuberculosis therapy.
Although the guidelines for the management of antituberculosis drug induced hepatitis have been
published from varieties of health institutes and organizations, they are to a great extent highly sim-
ilar, there are nevertheless some important differences.
We report a case of hepatitis in a renal transplant recipient admitted with pulmonary and extra
pulmonary (abdominal) tuberculosis and review the literature on this topic.
The introduction of antimicrobial teams, including specialist pharmacists, microbiologists and
infectious disease physicians, is a major factor to improve the quality of care and faces the overcom-
ing of antimicrobial resistance. Reintroducing one antituberculosis drug at a time with close mon-
itoring of liver enzymes seems to be the optimal approach in the management of antituberculosis
drug induced hepatitis.
With multi-disciplinary clinical approach the patient has been successfully cured and has returned
to normal active life.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.8 92828575.
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lsevier1. Introduction
Tuberculosis (TB) in solid organ transplant recipients occurs
mainly by the reactivation of latent disease and has been re-
lated to the type of organ transplanted, the level of immuno-
suppression, and concomitant opportunistic infections.
Hepatotoxicity is one of the main side-effects of the drugs used
in tuberculosis treatment. Pharmacists rounding with infec-
tious disease team (ID) play a vital role in improving the anti-
microbial therapy process, therapeutic drug monitoring and
the management of adverse drug reaction (Wada, 2005;
Tahaoglu et al., 2001; Lopez and Schluger, 2010; Weller and
Jamieson, 2004; Rapp, 2006) (Table 1).
Box 2 Discharge medications.
– Ethambutol 600 mg od
– Moxiﬂoxacin 400 mg od
– Isoniazid 300 mg od
– Rifabutin 300 mg od
– Pyridoxine 50 mg od
– Erythropoietin 30000 Il twice weekly
– Tacrolimus 4 mg bid
– Insulin biphasic 30 Il/day
182 Z. Al-SalmiWe report a case of hepatitis in a renal transplant recipient
admitted with pulmonary and extra pulmonary (abdominal)
TB and review the literature on this topic. The management
of hepatitis related to anti-tuberculosis, and the role of clinical
pharmacist is discussed. The Medline and Sumsearch dat-
abases were included in the literature review stage. The search
terms included in the literature review were: hepatitis, hepato-
toxicity, tuberculosis, anti-tuberculosis, renal transplantation,
infectious disease, and pharmacist.
Although the high rate of hepatitis associated with anti-
tuberculosis is well established, there is no consensus on the
clinical approach required for cases in which hepatotoxicity
has developed (Lopez and Schluger, 2010). Our patient had a
renal transplant and was taking immunosuppressants, which
made it more complicated. When admitted the patient ap-
peared weak, depressed, and without hope – most likely a sha-
dow of his former self because of previous experience with
therapy failure and long hospital stay. However, through mul-
ti-disciplinary clinical approach, the patient has returned to
normal active life.
2. Patient case presentation
A 28-year-old Omani native female, married, weighing 37 kg,
with a history of renal transplantation in 2006. One year after
transplantation, she presented to the Emergency Department
at the Royal Hospital (Muscat; Oman) with abdominal pain
and fever for the last 3 weeks. She was admitted under the
nephrology team, and then shifted to ID.
Before admission the patient was on maintenance immuno-
suppressive regimen of tacrolimus capsule 2.5 mg twice daily,
mycophenolate capsule 750 mg twice daily, and prednisolone
tablet 7.5 mg once daily.
The patient was not known to have had TB exposure and
had no recent travel history, and she was unaware of the results
of prior tuberculin skin testing. Tissue specimens obtained from
the gastro-intestinal tract revealed granulomatous inﬂamma-
tion with bacilli visible on acid-fast stain. Sputum microscopy
detected Mycobacterium tuberculosis by acid-fast stain provide
the preliminary conﬁrmation of pulmonary TB. The patient
was diagnosed with pulmonary and extra pulmonary (abdom-
inal) TB. She was isolated and Anti-Tuberculosis Therapy
(ATT) was initiated under the nephrology team, and included
isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and eth-
ambutol (ETH), with immunosuppressives to be continued (see
Box 1).
One week after starting ATT, the patient developed abnor-
mal liver function test (LFT), and a few days later the LFTBox 1 Current medication.
ATT
– Pyridoxine 50 mg OD
– Rifampicin 300 mg OD
– Ethambutol 600 mg OD
– INH 300 mg od
– Pyrazinamide 1200 mg od
Immunosuppressants
– Prednisolone 10 mg od
– Tacrolimus 2 mg od
– Mycophenolate 750 mg BIDdeteriorated and the patient was jaundiced with microcytic
anaemia (haemoglobin of 5 g/dL, normal range 11–18.0 g/
dL). The patient appeared weak, suffered a loss of appetite
(weight: 32 kg), and was febrile with a productive cough. She
received a blood transfusion, ATT withheld with close LFT
monitoring (Table 1). Three days later; the LFT improved
and ATT was resumed. Ten days after resuming ATT, the pa-
tient again developed abnormal LFT with elevations of alka-
line phosphatase to 368 IU/L (normal range 30–125 IU/L)
from baseline of 100 U/l, alanine aminotransferase to
264 IU/L (10–60 IU/L), and bilirubin to 240 lmol/L (3–
17 lmol/L). RIF was withheld until the bilirubin level became
normal. PZA was discontinued. ETH and INH were continued
and moxiﬂoxacin was added. The patient’s LFT normalized
within two weeks, rifabutin was introduced in the place of rif-
ampicin. Prednisolone and cyclosporine were stopped, and
tacrolimus was used as a single immunosuppressant. Insulin
was introduced as the patient’s blood glucose level was con-
stantly elevated. At this stage; the patient was febrile, and
was shifted out of the isolation room as a result of negative
culture. Two weeks later; the patient was discharged with an
appointment with nephrology and ID (see Box 2).
3. Discussion
The World Health Organization (WHO) reports on overcom-
ing antimicrobial resistance (WHO, 2000) and the European
Union ‘Copenhagen Recommendation’ is that antimicrobial
teams, including specialist pharmacists, microbiologists and
infectious disease physicians, be established in all the hospitals
(Weller and Jamieson, 2004). The Infectious Diseases Society
of America’s guidelines on improving the use of antimicrobial
agents in hospitals similarly encourages the introduction of
such teams (Lopez and Schluger, 2010; Marr et al., 1988).
The role of the ID clinical pharmacist in the UK includes
prescription monitoring, taking accurate medication histories,
provision of medicines’ information, patient counselling, and
regular liaison with the medical or surgical team and daily con-
tact with the patient, educating all grades of healthcare work-
ers and helping to develop policy. Such practice has been
shown to improve patient care and provide better, more
cost-effective, use of medicines (Schumock et al., 2003). The
addition of a dedicated antibiotic pharmacist to an active team
has been shown to beneﬁt patients by reducing medication er-
rors and the length of hospital stay, encouraging oral medica-
tion and ensuring appropriate drug choice (Weller and
Jamieson, 2004). These beneﬁts are achieved in a variety of
ways but central to the role of the antibiotic pharmacist is
the monitoring and enforcement of hospital antibiotic policy
(Lopez and Schluger, 2010; Weller and Jamieson, 2004).
Table 1 Pharmaceutical care plan for anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra
pulmonary tuberculosis.
Care issue/desired output Action
Continuity of relevant medicine on admission/
Ensure no discrepancies/omission from drug chart
Conﬁrm drug history, and ensure continuity of
relevant medicine on admission
Absence of actual/potential medication problems/
Ensure absence of medicine related problems
Screen patient medication for:
 Use renal excreted drugs
 Monitor drug–drug interaction between rifampi-
cin and immunosuppressive agents
Pulmonary and extra pulmonary (abdominal) TB/
Cure patient and prevent the transmission of
Mycobacterium tuberculosis to other persons.
– Patients with active pulmonary TB are isolated in
negative-pressure hospital rooms until they are
culture negative and susceptibilities conﬁrm that
the organism is susceptible to the treatment
Initial phase: 2-months of:
 isoniazid 5 mg/kg (maximum 300 mg/day)
 pyridoxine for patients receiving isoniazid to pre-
vent polyneuropathy. 25–50 mg orally daily dose
 rifampin 10 mg/kg (maximum 600 mg/day)
 pyrazinamide: 40–55 kg: 1,000 mg; 56–75 kg:
1,500 mg; 76–90 kg: 2,000 mg
 ethambutol: 40–55 kg: 800 mg; 56–75 kg:
1,200 mg; 76–90 kg: 1,600 mg
 The drugs are given once a day for 8 weeks (56
doses) continuation phase: 4-months of: isonia-
zid and rifampicin
Anti TB drug induced hepatitis (ATDH)/Normalize
LFT, avoid oﬀending drug and continue ATT
1. Screen lab results: Elevated LFT
2. Stop all ATT until LFT normalized
3. Start ATT one by one with close monitoring of
LFT
4. Start ethambutol and Isoniazid
5. Withhold rifampicin until bilirubin level goes
back to normal. Rifabutin in place of RIF
6. Do not re-start pyrazinamide
7. Start Moxiﬂoxacin
Post renal transplant on immunosuppressive agents/
To prevent graft rejection with safe and eﬀective
drug regimen
 Ensure suitable immunosuppressive regimen Rx,
avoid excessive immunosuppression
 Long-term corticosteroid and cyclosporine can
cause DM. Start Insulin
 Manage peripheral neuropathy
 TDM and dose adjustment to overcome the
interaction with rifampicin/rifabutin
Anaemia related to renal disease/To correct
haemoglobin level
 Blood transfusion
 Erythropoietin
 Dietician input
Discharging patient/Compliance with therapy,
Response to therapy, ADRs detection and
management
 Ensure patient knows all changes in drug
regimen
 Provide written information where possible
 Ensure keeping patient record for follow up care
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most cases of fully sensitive disease, usually involving INH and
RIF antibiotics, supplemented in the ﬁrst 2 months with PZA
and ETH antibiotics with the exception of TB involving the
CNS when treatment should be for one year (Thwaites and
et al., 2009). Guidelines for the management of antituberculo-
sis drug induced hepatitis (ATDH) have been published by the
American Thoracic Society (ATS), the British Thoracic Soci-
ety (BTS), the Task Force of the European Respiratory Soci-
ety, the WHO and the International Union against
Tuberculosis and Lung Disease (Blumberg et al., 2003; Joint
Tuberculosis Committee of the British Thoracic Society,
1998; Migliori et al., 1999; Navarro and Senior, 2006; Saukko-
nen et al., 2006). Although the guidelines from the ATS, BTS
and the Task Force are to a great extent highly similar, thereare nevertheless some important differences (Joint Tuberculo-
sis Committee of the British Thoracic Society, 1998).
Hepatotoxicity is one of the major side-effects of the med-
icines used in TB therapy (Tost et al., 2004). It seems that INH,
RIF and PZA each have hepatotoxic side-effects which in-
crease when the drugs are combined (Tahaoglu et al., 2001).
RIF is considered to be of low hepatotoxicity; but due to its
enzyme inducer effect it may enhance the toxicity of INH when
the two are combined (Tahaoglu et al., 2001). RIF has not
been shown to increase the toxicity of PZA, nor to have inter-
vened in its metabolism; however, more cases of hepatotoxicity
are observed in regimens containing two months of RIF and
PZA in HIV-negative patients than in those with INH (Jasmer
et al., 2002; Fatal and severe liver injuries associated with
rifampin and pyrazinamide for latent, 2001; WHO, 1992).
184 Z. Al-SalmiPZA hepatotoxicity depends on its dose, and the most offend-
ing hepatotoxic effect is seen at doses of 30 mg/kg/day. Rein-
troduction of PZA should be avoided once hepatotoxicity
occurs, as it increases the risk of recurrence (Tahaoglu et al.,
2001).
The hepatocellular pattern of liver injury, which is seen in
INH, RIF, PZA toxicity, has a predominant initial elevation
of alanine aminotransferase (Tostmann et al., 2008). There-
fore, this biochemical parameter is most often used to monitor
the liver function during ATT (Tostmann et al., 2008). In this
case, there was abnormal LFT with elevations of alkaline
phosphatase to 368 IU/L, alanine aminotransferase to
264 IU/L, and bilirubin to 240 lmol/L. The reintroduction of
the same regimen led to the same reaction, which conﬁrms
the causality. According to the WHO, a common deﬁnition
of ATDH is treatment-emergent increase in serum alanine
aminotransaminase greater than three or ﬁve times the upper
limit of normal, with or without symptoms of hepatitis, respec-
tively (WHO, 1992).
Once drug-induced hepatitis has resolved, the drugs are
reintroduced one at a time. If symptoms recur or liver func-
tion tests become abnormal as the drugs are reintroduced,
the last drug added should be stopped. Some advise starting
rifampicin because it is less likely than isoniazid or pyrazin-
amide to cause hepatotoxicity and is the most effective agent
(Guidelines for the prevention and management of Myco-
bacterium tuberculosis infection and disease in adult patients
with chronic kidney disease, 2010; World Health Organiza-
tion, 2010). After 3–7 days, isoniazid may be reintroduced.
In patients who have experienced jaundice but tolerate the
reintroduction of rifampicin and isoniazid, it is advisable
to avoid pyrazinamide.
Alternative regimens depend on which drug is implicated as
the cause of hepatitis. Reintroducing one drug at a time is the
optimal approach, especially if the patient’s hepatitis were se-
vere (World Health Organization, 2010). In this case; after
two trials with full dosage of ﬁrst line ATT, ID team changed
the treatment strategy by introducing one drug at a time. The
patient’s LFT normalized within two weeks. INH was started
with ETH. RIF was withheld until the bilirubin level became
normal. Then rifabutin was introduced in the place of RIF
for its lower liver enzymes induction activity. At this stage,
the patient was tolerating the new regimen, and LFT was con-
stantly normal. Therefore; the decision of discontinuing PZA
was made, and moxiﬂoxacin was added from the second line
ATT which has no hepatocellular toxicity, and is among the
newer quinolones that has the most in vitro activity against
M. tuberculosis, followed by levoﬂoxacin, oﬂoxacin, and cipro-
ﬂoxacin (Hu et al., 2003).
In a prospective study, forty ﬁve patients with new TB
developed hepatotoxicity after the ATT was randomized to a
drug regimen consisting of INH, RIF, ETM and streptomycin
(STR) administered by gradually increasing the number and
dosage of the drugs (group I). Patients in group II were re-
treated with the same regimen (isoniazid, rifampicin, pyrazin-
amide and ethambutol) in the same dosages throughout.
This study revealed that the rate of recurrence of hepatotoxic-
ity in the retreatment of tuberculosis is less than when pyrazin-
amide is not included in the regimen (Tahaoglu et al., 2001). In
this study, the most common predisposing factor of hepatotox-
icity was alcoholism, followed by being a carrier of VHB, and,
lastly, taking other hepatotoxic drugs. Another retrospectivestudy recommended in the presence of risk factors, to reduce
the dose of PZA to 20–25 mg/kg and not to re-introduce this
drug if hepatotoxicity occurs (Hu et al., 2003).
Organ transplantation places patients at an increased
chance of contracting TB. In the United States the risk of con-
tracting TB was estimated to be 20–74 times greater in trans-
planted patient than in the general population (Lopez and
Schluger, 2010). In general, transplanted kidney patients
should be managed with the standard ATT for 6 months
(Menzies et al., 2008).
It is important to exclude other potential causes before con-
cluding that the hepatitis is induced by the ATT. If the patient
is severely ill with TB and it is considered unsafe to stop TB
treatment, a non-hepatotoxic regimen consisting of streptomy-
cin, ethambutol and ﬂuoroquinolone (moxiﬂoxacin) should be
started (Guidelines for the prevention and management of
Mycobacterium tuberculosis infection and disease in adult pa-
tients with chronic kidney disease, 2010).
ATT interactions with immunosuppressive drugs are vital
and can lead to graft rejection. RIF is the drug which
mainly interferes with immunosuppressive agents by stimula-
tion of a number of liver enzymes including uridine diphos-
phate glucuronosyltransferases, monoamine oxidases,
glutathione S-transferases and cytochrome P450 (Chang
et al., 2007). The daily corticosteroid dose should be stepped
up to double the baseline dosage in patients taking RIF.
Cyclosporin level can be lowered when combined with
RIF, and it should be monitored and the dose modiﬁed
accordingly. Tacrolimus plasma levels need to be monitored
and the dose may be required to be increased (Chang et al.,
2007). RIF also interacts with mycophenolate mofetil by the
induction of hepatic, renal and gastrointestinal uridine
diphosphate glucuronosyltransferases and organic anion
transporters with resulting functional inhibition of enterohe-
patic recirculation of mycophenolate (Tostmann et al.,
2008). Once RIF has been stopped, liver enzyme induction
usually takes 2 weeks to return to normal. Therefore, the
dose of immunosuppressants will need to be reduced to
avoid accumulation and toxicity. In this case, RIF was
stopped and replaced by Rifabutin which has less liver en-
zymes induction activity, but dosage modiﬁcation of immu-
nosuppressants was still indicated. Patient’s blood glucose
was continually high, which may be due to the long term
administration of prednisolone and cyclosporine. In this
case, three clinical factors were indicating high level of
immunosuppression: Drug interactions, hyperglycaemia,
and multiple immunosuppressive agents. Such high level of
immunosuppression is not recommended. Therefore, prednis-
olone and cyclosporine were stopped, and tacrolimus was
used as a single immunosuppressant at a higher dosage.4. Conclusion
In conclusion: Hepatotoxicity is one of the major side-effects
of the medicines used in TB therapy. Reintroducing one drug
at a time with close monitoring of LFT seems to be the optimal
approach in the management of ATDH. With multi-disciplin-
ary clinical approach, pharmacist rounding with infectious dis-
ease team (ID) plays an integral role in improving
antimicrobial therapy process, therapeutic drug monitoring
and adverse drug reaction management.
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